The Thalidomide Trust: Questions and Answers
What is the Thalidomide Trust?
The Thalidomide Trust is the charity established to support people in the United Kingdom who were born with injuries caused by thalidomide. Its sole purpose is to provide financial assistance, practical support and services to beneficiaries while helping them meet the challenges associated with their Thalidomide related disabilities.
Who are the beneficiaries of the Thalidomide Trust?
Beneficiaries are UK connected individuals whose disabilities were caused by exposure to thalidomide during pregnancy. Many are now in later life and face increasing health challenges.
Why was the Thalidomide Children’s Trust set up?
It is important to understand that the original personal injury settlements and the creation of the Trust served different purposes. The personal injury settlements were intended to compensate individual beneficiaries for the physical injuries and deformities caused by thalidomide, based on an assessment of their disabilities at that time. They were not designed to fund the lifelong care, support and additional costs that would arise as beneficiaries grew older. Recognising that survivors would continue to face needs extending far beyond their original injuries, a separate Trust was established and funded by Distillers Company Ltd to provide ongoing support throughout beneficiaries' lives. The Trust was therefore not created from personal injury awards, nor was it intended to replace them. Rather, it existed alongside those awards to address the long-term practical consequences of living with thalidomide-related disabilities.
What role did Harold Evans play?
Public concern increased, led initially by parents of thalidomide children who argued that the original personal injury awards were inadequate for a lifetime of disability. Their campaign attracted wider support, including that of the newspaper editor Harold Evans, whose advocacy helped bring national attention to the issue. The resulting public pressure led to further negotiations with Distillers, the company responsible for marketing thalidomide in the UK. Those negotiations culminated in the establishment of the Thalidomide Children’s Trust, which was intended to provide continuing financial support and assistance throughout the lives of beneficiaries. For many survivors and their families, the creation of the Trust represented recognition that the original compensation settlements alone were insufficient to meet the long-term consequences of the thalidomide tragedy.
Why do some people believe the original compensation was inadequate?
Many thalidomide survivors believe that the original personal injury compensation settlements were inadequate because they were based solely on the injuries suffered by the children at the time and did not attempt to assess the lifetime consequences of those injuries. When the settlements were approved, the court did not undertake an assessment of future care needs, housing needs, equipment costs, support requirements, loss of earnings or the additional expenses associated with living a lifetime with severe disabilities. Indeed, the judge who sanctioned the settlement expressed the view that the court was not in a position to predict the future needs of the children. In addition, the settlements were reached against a background in which Distillers continued to deny legal liability. As a result, the children received only 40% of the damages that had been assessed according to the severity of their injuries. The remaining 60% was never paid.
Was the Trust designed to cover the 60% shortfall?
The Thalidomide Trust was never intended to represent, replace or somehow make up the balance of the personal injury compensation that beneficiaries did not receive. The original settlements and the Trust served fundamentally different purposes. The personal injury settlements were intended to compensate individuals for the physical injuries and deformities caused by thalidomide, whereas the Trust was established to provide continuing support for the lifelong practical consequences of living with those disabilities. The Trust's funds were not calculated as a substitute for the 60% of assessed damages that beneficiaries never received, nor were they ever presented as such. To regard Trust payments as offsetting the unpaid portion of beneficiaries' compensation is therefore to misunderstand both the purpose of the Trust and the basis upon which the original settlements were agreed. The fact that further funding had to be secured from Guinness in 1995 and from Diageo in 2005 demonstrates that the Trust was a separate support mechanism designed to meet ongoing needs, not a deferred payment of outstanding personal injury compensation.
If the children received compensation, why was the Thalidomide Trust needed?
The Trust was created because the original personal injury settlements did not address the long-term needs of survivors. The compensation paid to the children was compensation for their injuries. It was not intended to fund a lifetime of disability-related support, nor did it include an assessment of future care and support requirements. The Trust was established later, following public campaigning, to provide ongoing assistance for those lifetime needs.
How was the Thalidomide Children’s Trust funded?
The Trust's origins are unique. It was not created as a conventional charity supported by fundraising, but as a vehicle for administering compensation secured from Distillers Company Ltd following the thalidomide tragedy. As part of the 1973 settlement, Distillers agreed to establish a trust fund of approximately £14 million for the long-term benefit of those affected by thalidomide. At the time, the settlement was intended to support around 457 beneficiaries, equating to an average capital provision of approximately £30,600 per beneficiary for their lifetimes, although actual distributions depended on individual circumstances and assessments. The Trust's assets therefore originated from compensation intended for those directly affected by thalidomide, placing a particular responsibility on trustees to ensure that all resources are managed solely in the interests of beneficiaries.
How were Guinness forced to contribute?
By the early 1990s, given the inadequate sum paid by Distillers there were concerns that the Trust's resources would be insufficient to meet the lifetime needs of thalidomide survivors. Although Guinness, as the successor to Distillers Company Ltd, had previously denied any responsibility to provide further funding, beneficiaries and their supporters mounted a sustained campaign to secure a long-term solution. The campaign, led by Thalidomide UK and beneficiaries themselves, combined legal action, financial analysis and public advocacy. This included highly visible protests, hunger strikes and direct challenges to the company's leadership at Guinness AGMs, where pointed questions were put to the Board. Anthony Scrivener QC was brought in to lead the legal effort, supported by Jacqueline Perry, who played a central role in developing the legal case, and Stephen Ashcroft, whose financial work helped demonstrate the scale of the funding shortfall facing the Trust. Together, these efforts helped secure a landmark commitment from Guinness worth £37.5 million over 15 years, fundamentally strengthening the Trust's ability to support beneficiaries into later life.
What happened in 2005?
By 2005 it had become clear that, despite the earlier Guinness settlement, serious worries remained about the long-term financial security of the Thalidomide Trust. Beneficiaries were ageing, their health needs were increasing, and there was widespread anxiety that the existing arrangements would not provide adequate lifetime support. Thalidomide UK once again played a central role in the negotiations, supported by Jacqueline Perry KC and financial expert Stephen Ashcroft. Their work helped secure a new agreement with Diageo, the successor to Guinness and Distillers, which significantly increased the funding available to the Trust and extended financial support for many years into the future. The settlement was widely regarded as having secured the Trust's financial position and provided greater certainty for beneficiaries as they entered later life. For many beneficiaries, the 2005 settlement was every bit as important as the 1995 Guinness agreement. The 1995 campaign had secured £37.5 million over 15 years from a company that had previously denied responsibility, while the 2005 negotiations were aimed at ensuring that the Trust itself would remain viable and capable of meeting the evolving needs of thalidomide survivors. According to Thalidomide UK, the resulting Deed of Covenant with Diageo helped save the Trust from financial disaster.
So, are the beneficiaries well provided for by the Trust?
The answer depends on what comparison is being made. The Trust undoubtedly provides vital support and, without the additional funding secured from Guinness in 1995 and Diageo in 2005, many beneficiaries would have faced a far more uncertain future. However, it is important not to confuse Trust support with full compensation. Beneficiaries originally received only a proportion of their assessed personal injury damages, and the Trust was never intended to make good the balance. Its purpose was to provide ongoing assistance with the practical consequences of living with severe disabilities, not to compensate for the injuries themselves. As beneficiaries have grown older, many have experienced accelerating physical deterioration, increased care costs and reduced independence. The fact that successive campaigns were required to obtain substantial additional funding from Guinness and later Diageo demonstrates that the original arrangements were not sufficient to guarantee lifelong financial security. The question is therefore not whether the Trust provides valuable support, which it unquestionably does, but whether that support has ever placed beneficiaries in the position they would have been in had they received full compensation for their injuries. Many would argue that it has not.
What is the total amount that has been paid into the Thalidomide Trust?
Amazingly the agreement with Diageo, originally negotiated by TUK, is confidential. However, we estimate the total stands at £150 million.
Are the beneficiaries millionaires then?
Even if one assumes that the Trust has received a total of £150 million in funding since its creation, that figure needs to be viewed in context. Spread across 53 years and the 457 original beneficiaries, it equates to approximately £6,200 per beneficiary per year, or around £17 per day. That is before taking account of the significant administrative, professional and operational costs involved in running a national charitable trust currently just under £2 million per annum. While the Trust has undoubtedly provided valuable and often essential support, these figures illustrate why it was never intended to act as a substitute for the personal injury compensation that beneficiaries did not receive. The Trust was established to help address the practical challenges of living with severe disabilities over a lifetime, not to make good the 60% of assessed damages that remained unpaid. To suggest otherwise risks overstating the level of financial provision that beneficiaries have actually received and understating the scale of the losses and additional costs that many have carried throughout their lives.
Why are some beneficiaries concerned about governance of the Thalidomide Trust today?
Some beneficiaries have raised questions about governance, transparency, accountability, communication and decision-making within the Trust. Concerns may include how decisions are reached, how beneficiary views are taken into account and whether the organisation remains sufficiently focused on the needs and expectations of those it exists to serve.
What is governance?
Governance refers to the systems, rules and processes used to run an organisation. Good governance helps ensure that trustees act in the best interests of beneficiaries, manage resources responsibly and make decisions openly and fairly.
Who oversees the Thalidomide Trust?
Like other registered charities, the Trust is ultimately overseen by the relevant charity regulator and is governed by its trustees, who are responsible for ensuring that it complies with charity law and acts in accordance with its charitable purposes.
Why are some beneficiaries calling for change?
Many thalidomide survivors are now facing greater physical challenges than at any point in their lives. Some believe that the systems and support structures built decades ago should be reviewed to ensure they remain appropriate for the future needs of an ageing beneficiary population. In particular those beneficiaries are concerned that the original purposes of the Trust are not being adhered to.
What is the role of Thalidomide UK?
Thalidomide UK is an independent organisation that campaigns on issues affecting thalidomide survivors. It seeks to promote discussion, encourage accountability and advocate for measures that improve the long-term wellbeing, financial security and representation of beneficiaries.
What issues is Thalidomide UK currently campaigning on?
Campaigns include:
Improved governance and accountability.
Long-term financial security for survivors.
Historic taxation issues affecting beneficiaries.
Compensation-related issues.
Greater transparency and beneficiary engagement.
Calls for a public examination of unresolved aspects of the thalidomide story.
Has a complaint been made to the Charity Commission?
Thalidomide UK has submitted concerns regarding governance and related matters to the Charity Commission. The purpose of such referrals is to invite the regulator to consider whether any issues require further examination. A referral does not itself establish wrongdoing and any conclusions are a matter for the regulator.
Why does this matter now?
The average age of UK thalidomide survivors is increasing, and many are experiencing declining health and increasing dependency upon support services. Decisions taken today may have significant consequences for the quality of life and financial security of beneficiaries in the years ahead.
What does Thalidomide UK want to achieve?
Thalidomide UK seeks:
Greater transparency.
Strong governance.
Meaningful beneficiary engagement.
Improved accountability.
Long-term financial security.
Fair treatment of all beneficiaries.
A sustainable future for the thalidomide community.
How can beneficiaries become involved?
Beneficiaries can follow campaign updates, read published materials, contribute their views and participate in discussions about the future of support, representation and advocacy within the thalidomide community. If they wish they can join the campaign on this and other issues.
Where can I learn more?
For further information about current campaigns, governance issues, compensation, taxation and support for thalidomide survivors, explore the resources and press releases available on the Thalidomide UK website.
